1. Home
  2. ARDX vs RCUS Comparison

ARDX vs RCUS Comparison

Compare ARDX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • RCUS
  • Stock Information
  • Founded
  • ARDX 2007
  • RCUS 2015
  • Country
  • ARDX United States
  • RCUS United States
  • Employees
  • ARDX N/A
  • RCUS N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARDX Health Care
  • RCUS Health Care
  • Exchange
  • ARDX Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • ARDX 882.9M
  • RCUS 906.4M
  • IPO Year
  • ARDX 2014
  • RCUS 2018
  • Fundamental
  • Price
  • ARDX $5.97
  • RCUS $10.40
  • Analyst Decision
  • ARDX Strong Buy
  • RCUS Buy
  • Analyst Count
  • ARDX 9
  • RCUS 8
  • Target Price
  • ARDX $10.50
  • RCUS $20.71
  • AVG Volume (30 Days)
  • ARDX 4.4M
  • RCUS 805.6K
  • Earning Date
  • ARDX 08-04-2025
  • RCUS 08-06-2025
  • Dividend Yield
  • ARDX N/A
  • RCUS N/A
  • EPS Growth
  • ARDX N/A
  • RCUS N/A
  • EPS
  • ARDX N/A
  • RCUS N/A
  • Revenue
  • ARDX $386,146,000.00
  • RCUS $262,000,000.00
  • Revenue This Year
  • ARDX $10.10
  • RCUS N/A
  • Revenue Next Year
  • ARDX $32.38
  • RCUS $28.73
  • P/E Ratio
  • ARDX N/A
  • RCUS N/A
  • Revenue Growth
  • ARDX 83.88
  • RCUS 6.07
  • 52 Week Low
  • ARDX $3.21
  • RCUS $6.50
  • 52 Week High
  • ARDX $7.18
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 82.99
  • RCUS 63.56
  • Support Level
  • ARDX $4.08
  • RCUS $9.73
  • Resistance Level
  • ARDX $5.31
  • RCUS $10.23
  • Average True Range (ATR)
  • ARDX 0.24
  • RCUS 0.53
  • MACD
  • ARDX 0.12
  • RCUS 0.07
  • Stochastic Oscillator
  • ARDX 97.93
  • RCUS 82.11

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: